Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_assertion type Assertion NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_head.
- NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_assertion description "[Assuming a very low prior probability of 0.000001, similar to a probability assumed for a randomly selected single-nucleotide polymorphism in a genome-wide association study, and statistical power to detect an OR of 1.5, 4 associations were considered noteworthy as denoted by an FPRP value <0.2: GSTM1 null and bladder cancer (OR, 1.5; 95% CI, 1.3-1.6; P = 1.9 x 10(-14)), NAT2 slow acetylator and bladder cancer (OR, 1.46; 95% CI, 1.26-1.68; P = 2.5 x 10(-7)), MTHFR C677T and gastric cancer (OR, 1.52; 95% CI, 1.31-1.77; P = 4.9 x 10(-8)), and GSTM1 null and acute leukemia (OR, 1.20; 95% CI, 1.14-1.25; P = 8.6 x 10(-15)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_provenance.
- NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_assertion evidence source_evidence_literature NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_provenance.
- NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_assertion SIO_000772 18505952 NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_provenance.
- NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_assertion wasDerivedFrom befree-2016 NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_provenance.
- NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_assertion wasGeneratedBy ECO_0000203 NP673361.RAN8aqXFoH-SAvoPKwJjbO9JoDJDE4aGXYagsPaGpqk-8130_provenance.